Doxifluridine (5'-dFUrd) in patients with advanced colorectal carcinoma. A phase II study

Cancer Chemother Pharmacol. 1985;15(2):161-3. doi: 10.1007/BF00257528.

Abstract

Infusion of 5'-dFUrd (2.0-3.0 g/m2 over 1 h on days 1-5 every 3rd week) resulted in one partial response in 21 patients with advanced and progressing colorectal cancer. No patient had received chemotherapy before the 5'-dFUrd trial. Hematological and gastrointestinal toxicity were generally mild. In 4 patients peripheral neurotoxicity was diagnosed during treatment, whereas transient cerebellopathy was observed in one. Cardiac side effects (repeated angina pectoris following 5'-dFUrd infusion) led to discontinuation of treatment after two courses in one patient. It is concluded that 5'-dFUrd at the above doses is not superior to conventional 5-FU treatment in colorectal cancer. Neurological and cardiac side effects are rare but may be a problem in individual patients.

Publication types

  • Case Reports
  • Comparative Study

MeSH terms

  • Angina Pectoris / chemically induced
  • Brain Diseases / chemically induced
  • Carcinoembryonic Antigen / analysis
  • Colonic Neoplasms / drug therapy*
  • Drug Evaluation
  • Electromyography
  • Female
  • Floxuridine / adverse effects
  • Floxuridine / therapeutic use*
  • Fluorouracil / therapeutic use
  • Humans
  • Male
  • Middle Aged
  • Peripheral Nervous System Diseases / chemically induced
  • Rectal Neoplasms / drug therapy*

Substances

  • Carcinoembryonic Antigen
  • Floxuridine
  • Fluorouracil